Multiplex PCRs have been designed for including species other than Aspergillus fumigatus for the diagnosis of invasive aspergillosis, such as microarrays, liquid-phase array, and electrospray-ionization mass spectrometry (PCR/ESI MS). These methods are based on the selection of multiple primers to amplify different species with the specificity checked by hybridization to a probe or by base composition of the amplicon for the PCR/ESI MS. When testing complex samples such as respiratory specimens, some clinically relevant species can be missed. Indeed, it is impossible to design primers able to amplify all the known fungal species with the same efficiency. Therefore, the best amplified species may not be the most clinically relevant. Multiplex assays have also been proposed to detect A. fumigatus DNA and azole resistance. Since the gene responsible for azole resistance is single copy and the gene used for detection is multicopy, only the high fungal loads can be evaluated. Thus, although interesting for investigating mycobiome, the multiplex assays should be used with cautious for the diagnosis of IA or the detection of resistance. For the diagnosis of invasive aspergillosis, validated quantitative PCRs specifically targeting A. fumigatus or a limited set of species to increase sensitivity is a safer option.
Introduction
The microbiological diagnosis of invasive aspergillosisis (IA), mainly due to Aspergillus fumigatus, 1 includes pathology, direct examination, culture, and three surrogate biomarkers: the antigens galactomannan and (1→3)-β-Dglucan for which commercial assays are available, as well as fungal nucleic acids for which commercial and in-house polymerase chain reaction (PCR) assays have been developed. Given the difficulty to obtain biopsies in immunocompromised patients, the low sensitivity of classical microbiology, 2 and the rate of false positivity of galactomannan and the lack of specificity for IA of (1→3)-β-D-glucan, 3 PCR
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C The Author 2016. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com has been extensively studied for more than 20 years in the hope to overcome the limitations of the other methods. Recently, consensual technical requirement has been reached for performing diagnostic quantitative PCR on serum. 4, 5 One of the reasons why PCR is not included in the definition criteria of IA is the very low amount of Aspergillus DNA in blood or serum, 6, 7 which exacerbates all the limits and pitfalls of the diagnostic PCR assays. 8 In parallel, there are more and more reports of invasive fungal diseases due to moulds other than A. fumigatus, some of them requiring a specific treatment different from the treatment against A. fumigatus. [9] [10] [11] It is then tantalizing to develop a PCR assay able to include all these species. The goal of these PCR assays is then to increase the spectrum of the fungal species detected in a single tube without loosing the sensitivity for the detection of A. fumigatus. Additionally, several authors report the increasing incidence of azole resistant A. fumigatus isolates among patients either naïve of azole or under long-sustained azole therapy. 12 The high level of resistance in some area questions the use of azole as first line therapy. 13 There is therefore a need to detect azole resistance in the same time as the detection of A. fumigatus. Multiplex PCR, referring to the use of polymerase chain reaction to amplify several different DNA sequences simultaneously, appears to fulfil these different objectives. However, multiplexing raises several technical issues. The first one is to be able to amplify all the species with the same efficiency. A low sensitivity increases the risk of false negative results, which could lead to antifungal treatment cessation or to an inadequate antifungal choice. Sensitivity depends on a lot of factors from the nucleic acid extraction to the PCR itself including the mode of calculation (second derivative vs. fluorescence threshold) of the quantitative cycle (Cq). However, for multiplexing, the issue of the primer design is crucial.
Designing primers for multiplex use
The difficulties in developing primers able to amplify every species with the same efficiency are exemplified with the mycobiome studies. The goal is to amplify with one primer pair all the fungi present in the sample, to obtain sequences corresponding to OTU (operational taxonomic unit), and to infer from this result the number of fungi present in the sample tested. The objective of the PCR assay is to have the best representation of the species panel of one sample, if possible with respect of the relative quantification of each fungal species.
The first step for developing such assays is an in silico analysis of the sequences available for the fungi in databases. The in silico studies show that biases cannot be avoided, with some species more efficiently amplified than other, for instance, a better amplification of ascomycetes compared to basidiomycetes.
14 Due to the high polymorphism of the fungi, it is impossible to get primers able to amplify all the known fungal species without any mismatches with the targeted sequences. Therefore, a better amplification is expected with the species without any mismatches in the primer sequences, which can be neither the most abundant species nor the most clinically relevant species. The result does not represent the real image of the mixture of species in the initial sample but the image of the species that are the most easily amplified.
To complete in silico studies for the specific point of detection of the real mixtures, some authors have tested mock communities. 15 The number of fungal species and the relative abundance of the species are then perfectly controlled in the samples tested. It is therefore possible to compare the yield of primer pairs designed after in silico analyses. The observation is that no primer pair could reconstruct the known taxonomic distribution with perfect accuracy. Moreover, computational analysis of primer coverage and specificity cannot adequately predict behaviour under mixed biological conditions. 15 Of note the worst primers are the ITS1 primers, the most frequently used in mycobiome studies. 15 The main conclusion is then that biases are inevitable. Another way to evidence the biases due to primer choice is the difference observed between culture and high throughput sequencing methods. When performing whole genome sequencing (metagenomic) without any specific primers, the correlation with culture is satisfactory whereas using ITS primers (metaxonomic) the correlation is low. 16 
Impact of primer design for IA diagnosis
The mixture of several primer sets raises concern each time multiple sets of primers or primers designed for amplifying several species are used. The impossibility to design primers with no mismatches with all the fungal species must be taken into account when performing multiplex PCR assays for the diagnosis of IA. In serum or blood samples, the presence of contaminant non-fumigatus DNA in the sampling tubes is always a risk. 17 This undesirable DNA can come from environment, reagents, enzymes, antibiotics, other perfused products, or the tube itself. 18, 19 Panfungal primers increase the probability of amplifying environmental non-fumigatus DNA because nontargeted mould DNAs can then compete with A. fumigatus DNA during the amplification reaction. Since the A. fumigatus DNA has always been shown to be in a small amount in patients, 6 ,7 a little non-fumigatus DNA can prevent A. fumigatus amplification. The risk is then to amplify this non-fumigatus DNA and to miss the amplification of A. fumigatus DNA, leading to a false negative result. Of course, due to the ubiquitous feature of A. fumigatus, this environmental DNA can be A. fumigatus DNA. 18, 19 In this case, the risk is to detect A. fumigatus DNA not related to an infection, but one deals then with a false positive result not a false negative one. To limit the risk of these false positive results, some authors propose a threshold (e.g., Cq < 38 or <39) to keep only the high fungal loads more suggestive of ongoing IA. 20, 21 Similarly, the specificity of PCR positive results improves when considering the results on several consecutive blood samples: the rate of false positivity decreases from 21.5% with one isolated positivity to 3.8% with two PCR positive results. 22 However, in both strategies, the risk is to miss IAs with a very low circulating fungal load patients or very transient DNA release in blood stream. 6, 7 Moreover, if the PCR result has to be clinically relevant, the clinical decision of treating or not must be taken as soon as the first PCR is known. We showed that a single PCR positive sample accelerates the probability to have an IA when the patient is not already given antifungal drugs. 23 To aid the clinical decision when dealing with a first PCR positive result, we agree with the recent metaanalysis on the interest to add antigen detection. 22, 24 In bronchoalveolar lavage (BAL) and respiratory specimens, the presence of several fungal species, including yeasts and moulds, is expected. Whereas in blood the probability to have contaminant environmental DNA is low, in respiratory specimens, the presence of spores of multiple species is highly frequent. 25 The risk of missing the amplification of the virulent species is therefore higher than in blood if multiplex formats are used. [26] [27] [28] With respiratory samples, the risk of overrepresenting a species can also come from the DNA extraction step. Indeed, in complex specimens, a unique DNA extraction is used and is probably not optimal for every microorganism: the wall of yeasts is easier to break down than that of mould, for instance. If some species are more amenable to an efficient DNA extraction step, more DNA recovery is expected and, as a consequence, a better amplification. If for any reason, the DNA the best amplified is the one of environmental moulds with no clinical significance, the risk is that it results in no amplification of the A. fumigatus DNA coming from a true IA, leading to a false negative result. On the other hand, as for blood specimens, to limit the risk of false positive results, some authors propose an optimal cut-off (Cq<36) based on receiver operator characteristic curves. 29 The risk is as for blood to miss IAs with a very low fungal load recovered in BAL. This also raises issue on the transportability of this threshold knowing that BAL procedures are highly variable between centers and the fluid recovery highly variable between patients.
Evaluation of different multiplex formats
Such unexpected results, that is, detection of irrelevant species and, more importantly, failure to detect clinically relevant species, have been reported with different multiplex assays and is therefore not restricted to a given format (Table 1) . With a DNA microarray targeting 14 fungal pathogens, samples from two out of six patients with proven or probable IA were negative. 27 Using the multiplexed PCR and 
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If the performance of these technologies for detecting and identifying fungi in complex media such respiratory specimens is not optimal, their performance dramatically improves when simplifying the number of potential fungi, for instance, when focusing on positive blood bottles, or for the moulds, on tissue biopsies. [30] [31] [32] The possibilities of mismatches of the primer is then reduced, hence the improvement in amplification, and therefore in identification. When the assay is used for identification of colonies obtained in culture, the performance of the identification for the targeted species is usually excellent whatever the method used; liquid-phase array, 33, 34 PCR-ESI-MS, 35, 36 or microarrays. 37 However, the question is then identification of the infecting strains rather than detecting every species present in respiratory specimens. 
Aspergillus viridinutans
A. fumigatus samples).
Aspergillus terreus Aspergillus flavus Aspergillus niger
On the other hand, when testing a multiplex PCR assay targeting a limited set of closely related species (Aspergenius, PathoNostics, Maastricht, the Netherlands), the analytical performance seems better with BAL samples (Table 1) . 29 Although no comparison is possible between these methods since the clinical samples and the study designs were completely different, the apparent better performance of this latter multiplex assay could rely on the lower number of species targeted compared to the other methods reported above.
Azole-resistant detection in a multiplex format
Although several mechanisms are involved in azoleresistance acquisition in A. fumigatus, 38 the main mechanism is substitutions in the 14a-sterol demethylase (CYP51A) associated or not with the insertion of a tandem repeat in its promoter. 12, 39 Since the cyp51A gene is single copy gene and A. fumigatus a haploid microorganism, the study of the gene sequence is technically simple. This can be achieved through complete gene sequencing with DNA from culture, 39, 40 which allows detection of new mutations, or sequencing of fragments including known mutations after nested PCR assays, [41] [42] [43] real-time PCR assays, 44 or minisequencing. 45 Because detection of A. fumigatus and azole resistance impacts the clinical decision, 13 it is relevant to associate both positive diagnosis of IA and azole resistance detection. In a retrospective study using multiplex PCRs, the azole resistance PCR was successful in 14 positive A. fumigatus PCR BAL fluid samples, of which two were mutant strains. 29 In this multiplex PCR assay, the diagnosis was achieved through the amplification of the 28S rRNA multicopy gene and the azole resistance through the amplification of the single copy cyp51A gene of A. fumigatus. One can expect amplification of the 28S gene and not the cyp51A gene when the fungal load is low. Therefore, the result can be validated only if the fungal load is high enough to allow amplification of a single copy gene. 21, 29 In blood and serum, given the low fungal loads mentioned above, 6,7 the detection of azole resistant is even more challenging. 21 Another limitation of the multiplex format is the absence of quantification of both the total fungal burden and the proportion of resistant mutant among the wild types. This can be a secondary question in immunocompromised patients: the detection of only one resistant isolate among multiple susceptible ones can justify a therapeutic adaptation given the risk of treatment failure. However, in chronically infected patients such as cystic fibrosis patients, the proportion of wild types versus mutant types over time could change without any clinical significance as long as antifungal drugs are not given to select the resistant isolates. Only a precise quantification of the two types could address this issue.
Conclusion-perspective
Multiplex PCR assays for use in complex biological specimens such as respiratory specimens expose to the amplification of unwished targets or to a suboptimal amplification of the mould of medical importance. If DNAs from different species are present in a clinical sample, the best amplified is the one either in the largest quantities or without any mismatches between the primer and the targeted sequences. If for any reason, the DNA the best amplified is the one of environmental moulds with no clinical significance, the risk is to have no amplification of the A. fumigatus corresponding to a true IA, leading to a false negative result. These technical issues are not specific to mycology and are encountered in genetics. 46 When quality control in genetics has been performed, the key factors influencing variations are the biological samples and human factors, rather than technical diversity. 47 To increase the probability to detect A. fumigatus DNA is then to use well-optimized quantitative PCR assays targeting this species. 48 Nevertheless, the risk is to miss the diagnosis of other mould infections. This can be partially solved by multiplex PCR assays. However, in waiting for a more routine use of metagenomic, to obtain reproducible results when starting with complex specimens, the wiser in our opinion is to maintain the number of moulds to be amplified as low as possible. We nevertheless suggest keeping a specific assay for A. fumigatus and not to multiplex it as long as any impact of the presence of other moulds has not been ruled out. The interest of limiting the numbers of targeted species is the possibility to validate all the parameters of the qPCR according to the MIQE requirements, 49 and more specially to provide quantitative information. If mutation detection is needed, sensitivity in clinical sample is by definition low due to the single copy feature of the cyp51A gene. Therefore, a negative result should be given together with the determination of the amount of A. fumigatus DNA in the sample. Nevertheless, multiplex PCRs have plenty of other applications such as the mycobiome. PCR amplification of phylogenetically conserved marker sequences with subsequent next-generation sequencing of the constructed amplicons library will be probably improved by testing different primer sets 50 and optimizing the preparation of the samples. 51 
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